X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Supporting opportunities for enhanced competition in the marketplace

By Andrew Powaleny  |    November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...   Read More

Opportunities to build upon enhanced competition for medicines in the marketplace

By David Korn  |    July 27, 2017
Last week, I presented at the U.S Food and Drug Administration’s (FDA) public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical...   Read More

What are REMS? These extra steps are helping protect patient health

By Bill Chin, M.D.  |    October 6, 2016
As a physician and chief medical officer at PhRMA, I know how important it is to ensure that patients have access to safe, innovative medicines to help them live longer, healthier lives. But...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates